Your session is about to expire
← Back to Search
Other
CX1739 - 900 mg for Respiratory Depression
Phase 2
Waitlist Available
Research Sponsored by RespireRx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up sequence #1 - 30 minutes
Awards & highlights
Summary
The study is an investigation to assess the capacity of ascending doses of CX1739 to antagonize the respiratory depressive effect of remifentanil. The study will also investigate whether ascending doses of CX1739 reduce the analgesic effect of remifentanil or alter the BIS measure of sedation and will evaluate the safety of CX1739 when used in conjunction with remifentanil.
Eligible Conditions
- Respiratory Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ sequence #1 - 30 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~sequence #1 - 30 minutes
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Respiratory depression
Secondary study objectives
Change in pupil size
Maintenance of sedation
Pain
+1 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: CX1739 - 900 mgExperimental Treatment1 Intervention
Study drug - high dose
Group II: CX1739 - 600 mgExperimental Treatment1 Intervention
Study drug - mid Dose
Group III: CX1739 - 300 mgExperimental Treatment1 Intervention
Study Drug - low dose
Group IV: PlaceboPlacebo Group1 Intervention
Placebo
Find a Location
Who is running the clinical trial?
RespireRxLead Sponsor
4 Previous Clinical Trials
348 Total Patients Enrolled
Duke UniversityOTHER
2,424 Previous Clinical Trials
3,066,066 Total Patients Enrolled
2 Trials studying Respiratory Depression
84 Patients Enrolled for Respiratory Depression
Richard PurcellStudy DirectorRespireRx Pharmaceuticals
Share this study with friends
Copy Link
Messenger